Honokiol: a potent chemotherapy candidate for human colorectal carcinoma.
ABSTRACT To investigate the anticancer activity of honokiol on RKO, a human colorectal carcinoma cell line in vitro and in vivo, and to evaluate its possible use in clinic.
In vitro anticancer activity of honokiol was demonstrated by its induction of apoptosis in tumor cells. We analyzed cell proliferation with MTT assay, cell cycle with flow cytosmeter, DNA fragment with electrophoresis on agarose gels. To test the mechanism of honokiol-induced apoptosis, Western blotting was used to investigate the factors involved in this process. The pharmacokinetics study of honokiol was tested by high phase liquid chromatography. In in vivo study, Balb/c nude mice were incubated with RKO cells. Honokiol was injected intraperitoneally every other day into tumor bearing Balb/c nude mice.
Our results showed that honokiol induced apoptosis of RKO cells in a time- and dose-dependent manner. At 5-10 microg/mL for 48 h, honokiol induced apoptosis through activating Caspase cascades. Pharmacokinetics study demonstrated that, honokiol could be absorbed quickly by intraperitoneal injection, and maintained in plasma for more than 10 h. In nude mice bearing RKO-incubated tumor, honokiol displayed anticancer activity by inhibiting tumor growth and prolonging the lifespan of tumor bearing mice.
With its few toxicity to normal cells and potent anticancer activity in vitro and in vivo, honokiol might be a potential chemotherapy candidate in treating human colorectal carcinoma.
- [Show abstract] [Hide abstract]
ABSTRACT: Angiogenesis is the formation of new capillaries from existing vessels. Vascular endothelial growth factor (VEGF) promotes this growth by stimulating endothelial cells, which form vessel walls and transport nutrients and oxygen to tissues. VEGF has been implicated in several diseases, such as cancer and gynecologic disorders. Antiangiogenic agents prevent VEGF from binding to its receptors on the endothelial cell surface, which inhibits vessel development. Antiangiogenic agents have been found to be effective in treating several gynecologic diseases, such as endometriosis and uterine fibroids. Natural products with respect to finding new compounds with antiangiogenic effects are interested. In this review, we have focused on the importance of natural products with antiangiogenic activity in treating some malignant and benign angiogenesis-related gynecological disorders, including endometriosis and uterine fibroids.Nutrition and Cancer 01/2014; · 2.70 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: We have shown previously that honokiol (HNK), a bioactive component of the medicinal plant Magnolia officinalis, inhibits growth of human prostate cancer cells in vitro and in vivo. However, the effect of HNK on androgen receptor (AR) signaling has not been studied. LNCaP, C4-2, and TRAMP-C1 cells were used for various assays. Trypan blue dye exclusion assay or clonogenic assay was performed for determination of cell viability. The effects of HNK and/or its analogs on protein levels of AR and its target gene product prostate specific antigen (PSA) were determined by western blotting. RNA interference of p53 was achieved by transient transfection. Reverse transcription-polymerase chain reaction was performed for mRNA expression of AR. Nuclear level of AR was visualized by microscopy. Apoptosis was quantified by DNA fragmentation assay or flow cytometry after Annexin V-propidium iodide staining. HNK and its dichloroacetate analog (HDCA) were relatively more effective in suppressing cell viability and AR protein level than honokiol epoxide or biseugenol. Nuclear translocation of AR stimulated by a synthetic androgen (R1881) was markedly suppressed in the presence of HNK. Downregulation of AR protein resulting from HNK exposure was attributable to transcriptional repression as well as proteasomal degradation. HNK-mediated suppression of AR protein was maintained in LNCaP cells after knockdown of p53 protein. HNK-induced apoptosis was not affected by R1881 treatment. The present study demonstrates, for the first time, that HNK inhibits activity of AR in prostate cancer cells regardless of the p53 status. Prostate © 2013 Wiley Periodicals, Inc.The Prostate 12/2013; · 3.84 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: As fecal excretion is one of important routes of elimination of drugs and their metabolites, it is indispensable to investigate the metabolites in feces for more comprehensive information on biotransformation in vivo. In this study, a sensitive and reliable approach based on ultra-performance liquid chromatography/quadrupole-time-of-flight-mass spectrometry (UHPLC-Q-TOF-MS) was applied to characterize the metabolic profile of honokiol in rat feces after the administration of an equimolar mixture of honokiol and [(13)C6]-labeled honokiol. Totally 42 metabolites were discovered and tentatively identified in rat feces samples, 26 metabolites were first reported, including two novel classes of metabolites, methylated and dimeric metabolites of honokiol. Moreover, this study provided basic comparative data on the metabolites in rat plasma, feces and urine, which gave better understanding of the metabolic fate of honokiol in vivo.Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 02/2014; 953-954C:20-29. · 2.78 Impact Factor
PO Box 2345, Beijing 100023, China World J Gastroenterol 2004;10(23):3459-3463
Fax: +86-10-85381893 World Journal of Gastroenterology
E-mail: firstname.lastname@example.org www.wjgnet.com Copyright © 2004 by The WJG Press ISSN 1007-9327
• COLORECTAL CANCER •
Honokiol: A potent chemotherapy candidate for human colorectal
Fei Chen, Tao Wang, Yi-Feng Wu, Ying Gu, Xiao-Li Xu, Shu Zheng, Xun Hu
Fei Chen, Tao Wang, Ying Gu, Xiao-Li Xu, Shu Zheng, Xun Hu,
Cancer Institute, Second Affiliated Hospital of Zhejiang University,
Hangzhou 310009, Zhejiang Province, China
Yi-Feng Wu, Life Science College, Zhejiang University, Hangzhou
310027, Zhejiang Province, China
Supported by Cheung Kong Scholars Programme of National Ministry
of Education, China, and Li Ka Shing Foundation, Hong Kong
Co-first-authors: Fei Chen and Tao Wang
Correspondence to: Professor Xun Hu, Cancer Institute, Second
Affiliated Hospital of Zhejiang University, Hangzhou 310009, Zhejiang
province, China. email@example.com
Telephone: +86-571-87783868 Fax: +86-571-87214404
Received: 2004-02-14 Accepted: 2004-02-24
AIM: To investigate the anticancer activity of Honokiol on RKO,
a human colorectal carcinoma cell line in vitro and in vivo,
and to evaluate its possible use in clinic.
METHODS: In vitro anticancer activity of honokiol was
demonstrated by its induction of apoptosis in tumor cells.
We analyzed cell proliferation with MTT assay, cell cycle with
flow cytosmeter, DNA fragment with electrophoresis on
agarose gels. To test the mechanism of honokiol-induced
apoptosis, Western blotting was used to investigate the factors
involved in this process. The pharmacokinetics study of
honokiol was tested by high phase liquid chromatography.
In in vivo study, Balb/c nude mice were incubated with
RKO cells. Honokiol was injected intraperitoneally every
other day into tumor bearing Balb/c nude mice.
RESULTS: Our results showed that honokiol induced apoptosis
of RKO cells in a time- and dose-dependent manner. At
5-10 ug/mL for 48 h, honokiol induced apoptosis through
activating Caspase cascades. Pharmacokinetics study
demonstrated that, honokiol could be absorbed quickly by
intraperitoneal injection, and maintained in plasma for more
than 10 h. In nude mice bearing RKO-incubated tumor, honokiol
displayed anticancer activity by inhibiting tumor growth and
prolonging the lifespan of tumor bearing mice.
CONCLUSION: With its few toxicity to normal cells and
potent anticancer activity in vitro and in vivo, honokiol might
be a potential chemotherapy candidate in treating human
Chen F, Wang T, Wu YF, Gu Y, Xu XL, Zheng S, Hu X. Honokiol:
A potent chemotherapy candidate for human colorectal
carcinoma. World J Gastroenterol 2004; 10(23): 3459-3463
In traditional Chinese medicine, Houpu (Magnolia officinalis)
has long been one of the important herbs. It is widely used by
Chinese people in treating thrombotic stroke, typhoid fever,
anxiety and nervous disturbance when used in combination
with other herbs. With its major active constituent extracted
from the bark of Houpu, honokiol has been found having a
variety of pharmacological effects, such as anti-inflammatory,
antithrombotic, anti-arrhythmic, antioxidative and
anxiolytic effects. Recently, honokiol has been reported to
exhibit a potent cytotoxicity by inducing cell apoptosis in rat
and human leukemia cells[7,8], human fibrosarcoma cells,
human squamous lung cancer CH27 cells and human SVR
angiosarcoma cells, yet there has been no report on honokiol
in the treatment of human colorectal carcinoma.
Previous studies have shown that honokiol can induce
apoptosis with characteristic morphological changes and DNA
fragments, involvement of Caspase family and Bcl-2 family.
It could reduce tumor volume of SVR angiosarcoma in nude
mice. However, it is still unclear whether honokiol can be
used as a monomer in clinic. In this study, we chose colorectal
carcinoma cells to investigate its possible application in clinical
MATERIALS AND METHODS
Cell line and reagents
Human colorectal cell line RKO was provided by the Cancer
Institute of Zhejiang University. Cells were maintained in RPMI-
1640 medium (Gibco BRL) supplemented with 100 mL/L heat-
inactivated fetal bovine serum (Si-Ji-Qing Biotechnology Co,
Hangzhou, China), 100 U/mL penicillin and 100 µg/mL
streptomycin at 37 in a 50 mL/L CO2 atmosphere. Antibodies
used in this study including Caspases-3, -9 and pan-actin were
purchased from NeoMarkers, Fremont, CA, USA. Honokiol was
obtained from the National Institute for Pharmaceutical and
Biological Products, Beijing, China. The drug was dissolved in
dimethyl sulfoxide (DMSO) at the stock concentration of
10 g/L. It was further diluted in culture medium at the final
DMSO concentration <1%. 3-(4, 5-dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide (MTT) was purchased from
Sigma Chemical Corporation, USA. Six weeks old female Balb/
c mice and female BALB/c nude mice (weighing 20±2 g each)
were provided by the Experimental Animal Center of Zhejiang
Cell proliferation assay
Cells (1×104 in 100 µL) were seeded on 96-well plates in triplicate.
Following a 24-h- culture at 37
with fresh medium at various concentrations of honokiol in a
final volume of 200 µL. Cells were incubated at 37
Then 50 µL of MTT (2 mg/mL in PBS) was added to each well,
incubated for an additional 4 h, the plate was centrifuged at
1 000 r/min for 10 min, then the medium was removed. MTT
formazan precipitate was dissolved in 100 µL of DMSO, shaken
mechanically for 10 min and then read immediately at 570 nm in
a plate reader (Opsys MR, Denex Technology, USA).
, the medium was replaced
for 68 h[12,13].
Morphological changes and detection of DNA fragmentation
RKO cells were exposed to a variety of concentrations of
honokiol for 24 h, then examined under reverse microscope
(Olympus) and imaged with a digital camera. To detect DNA
fragments, the cells were collected and lysed with lysis buffer
containing 50 mmol/L Tris-HCL (pH 7.5), 20 mmol/L EDTA, and
10 g/L NP-40. Then 10 g/L SDS and RNase (5 µg/mL) were
added to the supernatants, and incubated at 56
followed by incubation with proteinase K (2.5 µg/mL) at 37
for 2 h. After the DNA was precipitated by addition of both
ammonium acetate (3.3 mol/L) and ethanol (99.5 %), it was
dissolved in a loading buffer. DNA fragmentation was detected
by electrophoresis on 15 g/L agarose gels and was visualized
with ethidium bromide staining.
for 2 h,
Cell cycle analysis by FCM
Honokiol-treated RKO cells and vehicles were fixed with
700 mL/L alcohol for 15 min at 4
propidium dodide (PI, Sigma, USA). The red fluorescence of
DNA-bound PI in individual cells was measured at 488 nm with
a FACSCalibur (Becton Dickinson, USA) and the results were
analyzed using ModFit 3.0 software. Ten thousand events were
analyzed for each sample.
, then stained with 1.0 µg/mL
Western blot assay
RKO cells (5×106) were lysed by 4 g/L trypsin containing 0.2 g/L
EDTA, then collected after washed twice with phosphate-
buffered saline (PBS, pH 7.4). Total protein extracts from the
cells were prepared using cell lysis buffer [150 mmol/L NaCl,
0.5 mol/L Tris-HCL (pH 7.2), 0.25 mol/L EDTA (pH 8.0), 10 g/L
Triton X-100, 50 mL/L glycerol, 12.5 g/L SDS]. The extract (30 µg)
was electrophoresed on 120 g/L SDS-PAGE gel and electroblotted
onto polyvinydene difluoride membrane (PVDF, Millipore Corp.,
Bedford, MA) for 2 h in a buffer containing 25 mmol/L Tris-HCL
(pH 8.3), 192 mmol/L glycine and 200 mL/L methanol. The blots
were blocked with 50 g/L nonfat milk in TBST washing buffer
for 2 h at room temperature and then incubated at 4
with anti-caspase-3 and -9 antibodies (NeoMarkers), all of which
were diluted 1:400 in TBST. After washed at room temperature
with washing buffer, they were labeled with peroxidase-
conjugated secondary antibodies.
Cell toxicity on primary cells
Primary human fibroblast cells were derived from fresh skin.
Human monocytes were isolated from umbilical blood by Ficoll-
Hyaque separation method while seeded in 96-well microplates
at the concentration of 5 µg/mL phytohemagglutinin (PHA).
HUVECs isolated from fresh human umbilical cords were
inoculated into 96-well microplates at 5 000 cells/well. Following
treatment with the concentrations of 5, 10, 20, 40 µg/mL of honokiol
for 24 h, cell viability was estimated by trypan blue exclusion.
Three wells were measured at each time point/concentration.
Six wells were measured for each concentration of test compound.
All toxicity experiments were at least repeated three times.
For intraperitoneal (ip) pharmacokinetics study, honokiol was
mixed with PEG400/dextrose by 7:3 in volume at a concentration
of 20 g/L. Thirty Balb/c mice received honokiol by i.p. at a dose of
250 mg/kg. Blood samples were collected as described. The
plasma concentrations were tested by the total fluorescence
intensity at 290 nm with high phase liquid chromatograph (HPLC,
HEWLETT PACKARD). Chromatography was carried out
using a Hypersil C18 column (5 mm×100 mm×2.1 mm) with a flow
rate of 0.2 mL/min. Pharmacokinetic parameters were estimated
by Modkine programs (Biosoft, UK).
In vivo efficacy evaluation
Effect of honokiol on ascites formation in Balb/c nude mice
Five Balb/c nude mice in each group were transplanted with
1×107 RKO cells by ip. Honokiol was dissolved in PEG400/
Tween 20 (9:1 by volume). Honokiol-treated group was
intragastrically administered 2 mg of honokiol per mice on d 0,
2, 4, 6, 8 and 10 after inoculation of RKO cells. While the control
group was given the same volume of PEG400/Tween20. Animals
were regularly monitored for the appearance of peritoneal bulge
and body weight.
Effect of honokiol on solid tumor growth in Balb/c nude mice
RKO cells (5×106) were injected subcutaneously at the axilla of
Balb/c nude mice. When tumors became visible about one week
after implant, the animals were randomized into four groups:
Adriamycin-treated, honokiol-treated, vehicle and control. All
mice received ip injection on days 8-11, 14-17, 21-24 and 28-31.
Each mouse of honokiol-treated group received 80 mg/(kg/d)
of honokiol suspended in PEG400/dextrose (7:3 by volume)
intraperitoneally, while vehicle given equivalent solvent of
PEG400/dextrose. Adriamycin dissolved in saline was injected
ip at a dose of 2 mg/kg. Mice of control group were given the
same volume of saline. Tumor growth was monitored with
calipers every other day, and tumor volume was calculated
using the modified ellipsoid formula: A/6×A×B2, where A is the
longer axis and B is the axis perpendicular to A (Figure 1).
Figure 1 Chemical structure of honokiol (C18H18O2, MW = 266.33).
Values were given as mean±SD. Statistical comparisons were
made by Student’s t-test, and P<0.05 was taken as significant.
Inhibition of RKO cell proliferation
Cells treated with honokiol resulted in a dose- and time- dependent
cytotoxicity in RKO cells. As shown in Figure 2A, honokiol-
mediated cytotoxicity occurred at the concentration of 5 µg/mL
and above. A significant decrease in cell number was seen at
10 µg/mL. The concentration leading to a 50% decrease in cell
number (IC50) was about 12.47 µg/mL. Moreover, treatment of
RKO cells with 5 µg/mL or 10 µg/mL of honokiol resulted in a
significant growth inhibition at various time points (Figure 2B).
Morphological changes and DNA fragmentation detection in
According to MTT results, we chose 5, 10, 15 µg/mL of honokiol
to detect molecular changes. Under an inverted phase contrast
microscope, honokiol-treated cells exhibited morphological
features of apoptosis (Data not shown): rounded and granulated
morphology, some vacuoles coming from cytoplasm, cell shrinkage
and eventually detached from culture plates. In honokiol-
treated cells, a degradation of chromosomal DNA into small
internucleosomal fragments was evidenced by the formation
of 180-200 bp DNA ladders on agarose gels (Figure 3), hallmark
of cells undergoing apoptosis. No DNA ladders were detected in
the samples isolated from control cultures. These results indicated
that honokiol induced an apoptotic cell death in RKO cells.
3460 ISSN 1007-9327 CN 14-1219/ R World J Gastroenterol December 1, 2004 Volume 10 Number 23
Figure 2 Concentration- and time-dependent inhibition of RKO
cells exposed to honokiol shown by MTT assay. (A) RKO cells
were plated in quadruplicate in 96-well plates and treated with
increasing concentrations of honokiol for 68 h. (B) RKO cells
treated with 5, 10 and 15 µg/ mL of honokiol were tested at
different time points.
Figure 3 Differences in vehicle or honokiol induced apoptotic
DNA laddering of RKO cells. lane 1: control; lane 2: 5 µg/ mL;
lane 3: 10 µg/ mL; lane 4: 15 µg/ mL.
Effect of honokiol on cell cycle analysis of RKO cells
RKO cells were exposed to increasing concentrations of
honokiol (5-15 µg/mL) for 48 h, and the growth of cells was
analyzed with flow cytometry. In the absence of honokiol, the
cell populations were at G1, S, and G2/M phases (Figure 4),
accompanied with increased concentrations of honokiol by a
concomitant increase of the G1 phase (Table 1). From Figure 4,
the peak areas of subdiploid were enlarged with increased
concentrations of honokiol. This observation led to a suggestion
of G1 arrest. DNA fragmentation was seen when the cells were
exposed to honokiol at 10 µg/mL and above (14.10% and 20.31%,
Table 1 Effect of honokiol on cell cycle distribution and
apoptosis of RKO cells
Cell cycle distribution (%)
Groups Apoptosis (%)
G2/ M G0/ G1 S
5 µg/ mL
10 µg/ mL
15 µg/ mL
aP<0.05, bP<0.01 vs corresponding control group. Cell cycle
distribution was determined after 48 h of treatment in each
group. The tabulated percentages were an average calculated
on the results of three separate experiments. The results were
represented by mean±SD (n = 3).
Caspase -3 and -9 expression by Western blot
Since Caspases are the main factors in the apoptotic pathway,
we investigated whether Caspases were involved in inducing
apoptosis of RKO cells treated with honokiol. Cells induced for
48 h were analyzed for protein expression by Western blot. The
results showed that Caspase-3 and -9 were up-regulated in a
dose-dependent manner (Figure 5).
Effects of honokiol on primary cultured cells
As shown in Figure 6, honokiol had little cytocidal effect
on primary human fibroblast cells and human lymphocytes
even up to 40 µg/mL. HUVEC cells after honokiol treatment
resulted in a sharply dose-dependent cytotoxicity. These
Chen F et al. Honokiol for treatment of human colorectal carcinoma 3461
Cell viability (% control)
0 5 10 15 20 25 30 35 40
12 24 36 48 72
1 2 3 4
Figure 4 Apoptosis of RKO cells detected by FCM. (A) control; (B) 5 µg/ mL; (C) 10 µg/ mL; (D) 15 µg/ mL.
0 20 40 60 80 100
0 20 40 60 80 100
0 20 40 60 80 100
0 20 40 60 80 100
results demonstrated that human fibroblast cells and
lymphocytes were more resistant to the honokiol-mediated
cytotoxicity than HUVECs.
Figure 5 Western blot analysis for the expression of Caspase-
3 and -9 in human colorectal carcinoma cell line RKO cells. Lane
1: vehicle; lane 2: 5 µg/ mL; lane 3: 10 µg/ mL.
Figure 6 Cytocidal effect of honokiol on the growth of primary
cultured human umbilical vein endothelial cells, primary hu-
man fibroblast cells and human lymphocytes.
The pharmacokinetics of honokiol was evaluated after
intraperitoneal injection of 250 mg/kg to BALB/c mice. The
maximum plasma concentration of honokiol was observed at
27.179±6.252 min after administration (Figure 7). The plasma
disappearance curve could best be described by a first-order
absorption one-compartment model, with an absorption
half-life of 10.121±2.761 min, and an elimination half-life of
5.218±0.461 h (Figure 7).
Figure 7 Honokiol concentration in plasma of BALB/ c mice.
Inhibition of tumor growth in nude mice implanted with RKO
We studied the effect of honokiol on the growth of RKO tumor.
There was significant inhibition of tumor growth by honokiol
(Table 2). All the control mice developed peritoneal bulge and
died by d 12. However, no peritoneal bulge was observed in
80% of the honokiol-treated animals and the mice survived for
up to 30 d. These observations indicated the anti-tumor activity
of honokiol in vivo (Table 2).
Table 2 Effect of honokiol on ascites growth of tumor in Babl/
c nude mice
Group Ascites MST Dead Living Survival percentage
(d) (D) (L) (L/ (D+L)×100%)
Control 5 10.7
Honokiol 1 34.3
MST: Mean survival time. RKO cells were transplanted
intraperitoneally. Honokiol was administered 2 mg per mice
on d 0, 2, 4, 6, 8, and 10 after tumor transplantation. The mice
were monitored for peritoneal bulge and survived for up to 30
d. Control mice died by d 12 of RKO inoculation.
Inhibition of solid tumor growth in nude mice bearing RKO cells
From Figure 8, animals in control and vehicle groups showed a
progressive increase in tumor volume, with a growth rate of
1627.6% and 1408.2% respectively on d 28. While in treated
groups, tumor growth rate was increased to 968.9% in adriamycin
group and 709.9% in honokiol-treated group. There was a
significant difference between honokiol-treated group and its
control (treated with PEG400/dextrose) (P<0.05). Similar results
were found between adriamycin-treated group and its control
(P<0.05). These data further confirmed that honokiol had an
effective anticancer activity in vivo.
Figure 8 Effect of honokiol on the growth of xenografted RKO
in Balb/ c nude mice. The Y-axis represents tumor volume, X-
axis represents time (day) after RKO cell inoculation.
Prolongation of life-span in nude mice bearing RKO solid tumor
The lifespan of mice in honokiol-treated group (80 mg/kg) was
monitored and compared to the vehicle and adriamycin-treated
group (Table 3). The mean survival time was 50.9 d in honokiol-
treated group, with a significant prolongation compared to vehicle
group (29.7 d, P<0.05). The survival rate in honokiol-treated group
was 176.7%, much higher than that in vehicle group (P<0.01).
There was no significant difference between control and vehicle
groups and between adriamycin-treated and honokiol-treated
groups. The results demonstrated that honokiol had a similar
effect to adriamycin in prolongation of lifespan of tumor-bearing
Table 3 Effect of honokiol on MST and T/ C% in Balb/ c nude
mice bearing RKO-incubated tumor
Group Number of mice MST (d) T/ c (%)
MST, mean survival time. The survival rate (T/ C%) was cal-
culated according to the following equation: T/ C (%) = [average
survival period in the test group/ average survival period in
the control group]×100. aP<0.05; bP<0.01 vs vehicle or control.
3462 ISSN 1007-9327 CN 14-1219/ R World J Gastroenterol December 1, 2004 Volume 10 Number 23
1 2 3
d 7 d 14 d 21 d 28 d 35
Tumor volume (cm3)
5 10 20 40 80
Cell viability (% control)
0 5 10 15 20 25
Many anticancer drugs kill tumor cells by inducing apoptosis.
Previous studies suggest that growth inhibition by honokiol
resulted from the induction of apoptosis in several cell lines[7-11].
A further study reported that in human squamous lung cancer
cells, honokiol induced apoptosis by down-regulating Bcl-XL
and sequentially activating Caspase cascade. Our results
confirmed this honokiol-mediated apoptotic progression in
cultured RKO cells.
A variety of compounds with potent anticancer activity in
vitro could not be used in clinic, one probable reason was due
to their strong toxicities to normal cells[17,18]. Therefore, we first
investigated honokiol’s effects on the toxicity of primary cultured
human cells. Our data demonstrated that the IC50s were much
higher in human fibroblasts and lymphocytes than in RKO
cells, with the exception that HUVECs were more sensitive to
honokiol. The safe doses for fibroblasts and lymphocytes could
be up to 40 µg/mL (Figure 6), much greater than that for RKO
and other tumor cells (data not shown). The phenomenon that
primary cultured endothelial cells were more sensitive to
honokiol might be related to the finding that honokiol had
antiangiogenesis activity by inhibiting VEGF and its receptor 2
in vitro. In chemotherapy, antiangiogenesis is another
important target besides apoptosis induction in tumor cells.
Based on the fewer toxicity to normal fibroblasts and
lymphocytes, we thus proposed that honokiol could be a safe and
potent candidate of chemotherapy for colorectal cancer in vivo.
Another major obstacle was that many potent agents were
poorly absorbed and quickly cleared in vivo, such as curcumin.
Curcumin was difficult to absorb in the gastrointestinal tract
and, even when systemically administered, it was rapidly cleared
by hepatic metabolism.
We then established two in vivo models with Babl/c nude
mice bearing RKO cells, the ascitic tumor model and the solid
tumor model. In RKO ascitic tumor model, honokiol exhibited a
strong efficiency in prolonging the lifespan of ascitic tumor
bearing mice and was highly effective on inhibiting intraperitoneal
ascites in Balb/c nude mice. In our another model, honokiol
also exhibited a potent efficiency in inhibiting solid tumor
growth. In RKO incubated tumor bearing mice, honokiol at
80 mg/kg significantly inhibited the tumor growth and
prolonged the lifespan compared to the vehicle (P<0.05). The
antitumor efficiency of honokiol was similar to that of the
commonly used chemotherapy drug, adriamycin.
The results of the present study are encouraging because
honokiol has shown significant inhibition of tumor growth
in vitro and in vivo, as well as prolongation of lifespan in
tumor-bearing mice in vivo. Together with its safety to human,
honokiol might be a promising chemotherapy candidate in
treating colorectal carcinoma or other cancers in clinic.
1 Squires RF, Ai J, Witt MR, Kahnberg P, Saederup E, Sterner O,
Nielsen M. Honokiol and magnolol increase the number of [3H]
muscimol binding sites three-fold in rat forebrain membranes
in vitro using a filtration assay, by allosterically increasing the
affinities of low-affinity sites. Neurochem Res 1999; 24: 1593-1602
2Liou K T, Shen YC, Chen CF, Tsao CM, Tsai SK. The anti-
inflammatory effect of honokiol on neutrophils: mechanisms in
the inhibition of reactive oxygen species production. Eur J
Pharmacol 2003; 475: 19-27
Teng CM, Chen CC, Ko FN, Lee LG, Huang TF, Chen YP, Hsu
HY. Two antiplatelet agents from Magnolia officinalis. Thromb
Res 1988; 50: 757-765
Liou K T, Lin SM, Huang SS, Chih CL, Tsai SK. Honokiol ame-
liorates cerebral infarction from ischemia-reperfusion injury in
rats. Planta Med 2003; 69: 130-134
Lo YC, Teng CM, Chen CF, Chen CC, Hong CY. Magnolol and
honokiol isolated from Magnolia officinalis protect rat heart
mitochondria against lipid peroxidation. Biochem Pharmacol
1994; 47: 549-553
K uribara H, Kishi E, Hattori N, Yuzurihara M, Maruyama Y.
Application of the elevated plus-maze test in mice for evalua-
tion of the content of honokiol in water extracts of magnolia.
Phytother Res 1999; 13: 593-596
Hirano T, Gotoh M, Oka K. Natural flavonoids and lignans are
potent cytostatic agents against human leukemic HL-60 cells.
Life Sci 1994; 55: 1061-1069
Hibasami H, A chiwa Y, Katsuzaki H, Imai K, Yoshioka K,
Nakanishi K, Ishii Y, Hasegawa M, Komiya T. Honokiol in-
duces apoptosis in human lymphoid leukemia Molt 4B cells.
Int J Mol Med 1998; 2: 671-673
Nagase H, Ikeda K, Sakai Y. Inhibitory effect of magnolol and
honokiol from Magnolia obovata on human fibrosarcoma HT-
1080. Invasiveness in vitro. Planta Med 2001; 67: 705-708
Yang SE, Hsieh MT, Tsai TH, Hsu SL. Down-modulation of
Bcl-Xl, release of cytochrome c and sequential activation of
caspases during honokiol-induced apoptosis in human squa-
mous lung cancer CH27 cells. Biochem Pharmacol 2002; 63:
Bai X, Cerimele F, Ushio-Fukai M, Waqas M, Campbell PM,
Govindarajan B, Der CJ, Battle T, Frank DA, Ye K, Murad E,
Dubiel W, Soff G, A rbiser JL. Honokiol, a small molecular
weight natural product, inhibits angiogenesis in vitro and tu-
mor growth in vivo. J Biol Chem 2003; 278: 35501-35507
A rbiser JL, Panigrathy D, Klauber N, Rupnick M, Flynn E,
Udagawa T, D’Amato RJ. The antiangiogenic agents TNP-470
and 2-methoxyestradiol inhibit the growth of angiosarcoma in
mice. J Am Acad Dermatol 1999; 40(6pt 1): 925-929
LaMontagne K R Jr, Moses MA, Wiederschain D, Mahajan S,
Holden J, Ghazizadeh H, Frank DA, Arbiser JL. Inhibition of
MAP kinase kinase causes morphological reversion and disso-
ciation between soft agar growth and in vivo tumorigenesis in
angiosarcoma cells. Am J Pathol 2000; 157: 1937-1945
Beddy D, Watson RW, Fitzpatrick JM, O’Connell PR. Increased
vascular endothelial growth factor production in fibroblasts
isolated from strictures in patients with Crohn’s disease. Br J
Surg 2004; 91: 72-77
Goldrosen MH, Gannon PJ, Lutz M, Hloyoke ED. Isolation of
human peripheral blood lymphocytes: modification of a double
discontinuous density gradient of Ficoll-Hypaque. J Immunol
Methods 1977; 14: 15-17
A grawal S, Jiang Z, Zhao Q, Shaw D, Cai Q, Roskey A ,
Channavajjala L, Saxinger C, Zhang R. Mixed-backbone oligonucle-
otides as second generation antisense oligonucleotides: in vitro and
in vivo studies. Proc Natl Acad Sci U S A 1997; 94: 2620-2625
Tsai TH, Chou CJ, Cheng FC, Chen CF. Pharmacokinetics of
honokiol after intravenous administration in rats assessed us-
ing high-performance liquid chromatography. J Chromatogr B
Biomed Appl 1994; 655: 41-45
Eikesdal HP, Bjerkvig R, Dahl O. Vinblastine and hyperther-
mia target the neovasculature in BT (4) AN rat gliomas: thera-
peutic implications of the vascular phenotype. Int J Radiat
Oncol Biol Phys 2001; 51: 535-544
Edited by Wang XL Proofread by Zhu LH and Xu FM
Chen F et al. Honokiol for treatment of human colorectal carcinoma 3463